U.S. Markets closed

Kiniksa Pharmaceuticals, Ltd. (KNSA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.50+0.35 (+2.47%)
At close: 4:00PM EDT

Kiniksa Pharmaceuticals, Ltd.

Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
808 189 6257
http://www.kiniksa.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees168

Key Executives

NameTitlePayExercisedYear Born
Mr. Sanj K. PatelCEO & Chairman1.43MN/A1970
Mr. Mark Ragosa C.F.A.Sr. VP & CFON/AN/A1975
Mr. Michael R. MegnaChief Accounting Officer & VP of Fin.N/AN/A1971
Mr. Chad MorinVP & Chief Compliance OfficerN/AN/AN/A
Ms. Madelyn ZeylikmanGen. CounselN/AN/AN/A
Ms. Melissa MannoChief HR OfficerN/AN/AN/A
Dr. John F. PaoliniSr. VP & Chief Medical OfficerN/AN/A1965
Mr. Rasmus Holm-JorgensenSr. VP, Chief Strategy & Portfolio OfficerN/AN/AN/A
Mr. Carsten BoessExec. VP of Corp. AffairsN/AN/A1967
Ms. Christine MaurerSr. VP of Program ManagementN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Corporate Governance

Kiniksa Pharmaceuticals, Ltd.’s ISS Governance QualityScore as of June 1, 2021 is 10. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.